Now Reading: Hogan Lovells advises on HK$611 million IPO and Chapter 18A listing of Cloudbreak Pharma Inc.
-
01
Hogan Lovells advises on HK$611 million IPO and Chapter 18A listing of Cloudbreak Pharma Inc.
Hogan Lovells advises on HK$611 million IPO and Chapter 18A listing of Cloudbreak Pharma Inc.
Hong Kong, 9 July 2025 – Global law firm Hogan Lovells has advised the issuer, Cloudbreak Pharma Inc., on its HK$611 million Initial Public Offering (IPO) and listing on the Main Board of the Hong Kong Stock Exchange under Chapter 18A of the Hong Kong Listing Rules for pre-revenue biotech companies.
Cloudbreak Pharma Inc. is an innovation-driven clinical-stage ophthalmology biotechnology company dedicated to the development of novel and differentiated treatments. It has established a broad and innovative pipeline of numerous drug candidates covering major anterior and posterior ophthalmic diseases, some of which are expected to be first-in-class drug therapies globally for the treatment of various eye diseases.
CCB International Capital Limited and Huatai Financial Holdings (Hong Kong) Limited acted as the Joint Sponsors and Overall Coordinators for the transaction.
Hong Kong corporate partner Sammy Li led the Hogan Lovells team, with support from counsel Samson Suen, senior associate Tiffany Lam and senior paralegal Vivian Siu. New York capital markets partner Richard Aftanas, senior associates David Wallace and Sophie Beutel provided US law advice. Los Angeles regulatory partner Robert Church, senior associate Eman Al-Hassan and associate Will Tenbarge provided US pharmaceutical and biotechnology regulatory legal advice.
